Clinical trial
A Phase IIb, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Partial Deep Dermal and Full Thickness Burns in Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)
NCT03229564 is registered in ClinicalTrials.gov with CUTISS AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Partial Deep Dermal and Full Thickness Burns in Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)
- Lead sponsor
- CUTISS AG
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 25, 2017
- Completion date
- June 30, 2028
- Enrollment
- 12 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.